众生药业(002317.SZ)：创新药昂拉地韦项目两项III期临床试验获顶线分析数据结果

Core Viewpoint - The announcement indicates that Zhongsheng Pharmaceutical's subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., has achieved positive results in Phase III clinical trials for its innovative drugs, Anladiwei granules and Anladiwei tablets, targeting influenza A in children and adolescents [1] Group 1 - The Phase III clinical trial for Anladiwei granules, aimed at treating influenza A in children aged 2 to 11, has shown positive efficacy and good safety [1] - The Phase III clinical trial for Anladiwei tablets, aimed at treating influenza A in adolescents aged 12 to 17, has also demonstrated favorable results [1] - Both trials have met their expected objectives, indicating a successful outcome for the company's research and development efforts [1]